210 related articles for article (PubMed ID: 8786290)
1. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells undergo rapid apoptosis in vitro during antigen-specific interaction with CD4+ T cells.
Matsue H; Edelbaum D; Hartmann AC; Morita A; Bergstresser PR; Yagita H; Okumura K; Takashima A
J Immunol; 1999 May; 162(9):5287-98. PubMed ID: 10228004
[TBL] [Abstract][Full Text] [Related]
3. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
4. The regulation of CD95 ligand expression and function in CTL.
Li JH; Rosen D; Ronen D; Behrens CK; Krammer PH; Clark WR; Berke G
J Immunol; 1998 Oct; 161(8):3943-9. PubMed ID: 9780162
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway.
Ashany D; Savir A; Bhardwaj N; Elkon KB
J Immunol; 1999 Nov; 163(10):5303-11. PubMed ID: 10553053
[TBL] [Abstract][Full Text] [Related]
6. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
[TBL] [Abstract][Full Text] [Related]
7. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.
Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V
J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis signaling pathways in normal T cells: differential activity of Bcl-2 and IL-1beta-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity.
Moreno MB; Memon SA; Zacharchuk CM
J Immunol; 1996 Nov; 157(9):3845-9. PubMed ID: 8892614
[TBL] [Abstract][Full Text] [Related]
10. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells.
Inaba M; Kurasawa K; Mamura M; Kumano K; Saito Y; Iwamoto I
J Immunol; 1999 Aug; 163(3):1315-20. PubMed ID: 10415029
[TBL] [Abstract][Full Text] [Related]
11. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
12. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
14. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
[TBL] [Abstract][Full Text] [Related]
15. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
16. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity.
Stalder T; Hahn S; Erb P
J Immunol; 1994 Feb; 152(3):1127-33. PubMed ID: 7507960
[TBL] [Abstract][Full Text] [Related]
17. CD95/CD95 ligand-mediated counterattack does not block T cell cytotoxicity.
Jekle A; Obst R; Lang F; Rammensee HG; Gulbins E
Biochem Biophys Res Commun; 2000 Jun; 272(2):395-9. PubMed ID: 10833425
[TBL] [Abstract][Full Text] [Related]
18. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system.
Eichhorst ST; Müerköster S; Weigand MA; Krammer PH
Cancer Res; 2001 Jan; 61(1):243-8. PubMed ID: 11196169
[TBL] [Abstract][Full Text] [Related]
19. Fas (CD95, APO-1) antigen expression and function in murine mast cells.
Hartmann K; Wagelie-Steffen AL; von Stebut E; Metcalfe DD
J Immunol; 1997 Oct; 159(8):4006-14. PubMed ID: 9378990
[TBL] [Abstract][Full Text] [Related]
20. T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.
Li-Weber M; Laur O; Dern K; Krammer PH
Eur J Immunol; 2000 Feb; 30(2):661-70. PubMed ID: 10671224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
